Pfizer can capitalize on drug withdrawal
499909
Pfizer Inc., the world&#39;s biggest drugmaker, may benefit from Merck &amp; Co.&#39;s withdrawal of Vioxx because Pfizer&#39;s competing pain medicine Celebrex hasn&#39;t been linked to increased risk of heart attacks and strokes.
485764
With the sudden failure of torcetrapib, Pfizer Inc.'s most important experimental product, financial analysts predict shares of the world's largest drugmaker could fall from 5 to 25 percent on Monday and that Pfizer will need to buy other products to fill the void.
511170
Now might be a great time to load up on cutting-edge drugmakers.
131381
Uncertainty is spreading like a cancer in the pharmaceutical investing world, and that&#39;s bad news for the segment&#39;s kingpin, Pfizer (NYSE: PFE).
378410
Large drug companies may have to swallow some bitter medicine, but that could be healthy for shareholders.
685744
The Medicines Company reacquires its own drug.
190069
The FDA issues a health advisory for a top Pfizer drug.
722145
Will Pfizer be able to offset the looming loss of Lipitor?
745709
At a research and development meeting for analysts on Nov. 30, Pfizer (PFE ) stayed on message all day long. Despite questions about possible safety issues with arthritis pain medication Celebrex, patent challenges
12098
Cleveland Clinic cardiologist Eric Topol was one of the first to point out the potential heart risk of Merck&#39;s (nyse: MRK - news - people ) withdrawn Vioxx and Pfizer&#39;s (nyse: PFE - news - people ) Celebrex.
147168
The approval of a new drug is a long-term opportunity.
106310
The US Food and Drug Administration is considering further regulatory measures, including withdrawal from the market, of Pfizer&#39;s arthritis treatment Celebrex.
341524
Americans recently were jolted about the safety of their prescription drugs when Merck announced in late September the biggest voluntary withdrawal of a drug in recent memory.
430908
This little drug maker has the potential for big profit, in both the U.S. and Europe.
29190
NEW YORK - The withdrawal of the arthritis drug Vioxx two weeks ago was a disaster for Merck. But it also put rival Pfizer in a fix.
114059
Pfizer Inc. said on Monday it plans to  sponsor a major clinical study to further assess the  cardiovascular safety of its arthritis drug Celebrex following  the withdrawal of Merck & Co.'s Vioxx, a drug in the same  class.
314927
The move may mark the beginning of a bigger retrenchment by Pfizer and the rest of the drug industry.